Abstract
The iR2 Regimen(Ibrutinib, Lenalidomide, and Rituximab) Is Active with a Manageable Safety Profile in Patients with Relapsed/Refractory Non-Germinal Center-like Diffuse Large B-Cell Lymphoma
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have